Your browser is no longer supported. Please, upgrade your browser.
MBIO Mustang Bio, Inc. daily Stock Chart
Mustang Bio, Inc.
Index- P/E- EPS (ttm)-1.30 Insider Own1.10% Shs Outstand26.29M Perf Week-20.32%
Market Cap117.52M Forward P/E- EPS next Y-1.15 Insider Trans- Shs Float15.45M Perf Month36.70%
Income-34.50M PEG- EPS next Q-0.27 Inst Own10.80% Short Float2.63% Perf Quarter1.59%
Sales0.05M P/S2350.33 EPS this Y-147.00% Inst Trans4.64% Short Ratio5.11 Perf Half Y-27.90%
Book/sh1.66 P/B2.69 EPS next Y-17.30% ROA-60.00% Target Price18.00 Perf Year-58.69%
Cash/sh1.55 P/C2.88 EPS next 5Y- ROE-65.10% 52W Range2.18 - 11.99 Perf YTD52.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.72% Beta-
Dividend %- Quick Ratio10.30 Sales past 5Y- Gross Margin- 52W Low105.05% ATR0.45
Employees6 Current Ratio10.30 Sales Q/Q- Oper. Margin- RSI (14)60.12 Volatility16.74% 11.14%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.50% Profit Margin- Rel Volume1.35 Prev Close4.31
ShortableYes LT Debt/Eq0.00 EarningsNov 13 Payout- Avg Volume79.52K Price4.47
Recom- SMA2017.57% SMA5033.51% SMA200-19.88% Volume107,507 Change3.71%
Dec-21-17Initiated Oppenheimer Outperform $18
Dec-20-18 12:22PM  Need To Know: Mustang Bio, Inc. (NASDAQ:MBIO) Insiders Have Been Buying Shares Simply Wall St.
08:30AM  Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm GlobeNewswire
Dec-17-18 09:40AM  MBIO: Mustang: A Steed on the Fast Track Zacks Small Cap Research
Nov-28-18 08:00AM  Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy GlobeNewswire
Nov-19-18 07:25AM  Investor Expectations to Drive Momentum within Lawson Products, Kingold Jewelry, Liberty Broadband, Mustang Bio, Artesian Resources, and MYnd Analytics Discovering Underlying Factors of Influence GlobeNewswire
Nov-13-18 04:20PM  Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Oct-30-18 08:00AM  Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope GlobeNewswire
Oct-16-18 02:52PM  What Investors Should Know About Mustang Bio Incs (NASDAQ:MBIO) Financial Strength Simply Wall St. +5.98%
Oct-15-18 08:00AM  Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer GlobeNewswire +6.83%
Oct-01-18 08:00AM  Mustang Bio to Present at 8th Annual Partnering Forum at Cell & Gene Meeting on the Mesa GlobeNewswire -5.71%
Sep-07-18 07:08AM  Mustang Bio Sees Hammer Chart Pattern: Time to Buy? Zacks
Sep-04-18 07:15AM  Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018 GlobeNewswire
Aug-30-18 08:00AM  Mustang Bio to Participate in September Investor Conferences GlobeNewswire
Aug-13-18 04:15PM  Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
08:00AM  Mustang Bio and St. Jude Childrens Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency GlobeNewswire
07:41AM  St. Jude and Mustang Bio enter into exclusive worldwide license agreement American City Business Journals
Aug-09-18 08:00AM  Mustang Bio to Present at 10th Annual Bioprocessing Summit GlobeNewswire
Aug-02-18 10:29AM  Special Report: Biotech incubator taps investors through in-house brokerage Reuters
09:55AM  Biotech incubator taps investors through in-house brokerage Reuters
Jul-19-18 08:30AM  Mustang Bio Completes Pre-IND Meeting with FDA for MB-102 (CD123 CAR T) GlobeNewswire
Jun-25-18 07:30AM  Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes GlobeNewswire
Jun-22-18 08:00AM  Mustang Bio Announces Opening of CAR T Cell Therapy Manufacturing Facility in Worcester, Mass. GlobeNewswire +5.39%
May-31-18 07:30AM  Mustang Bio to Present at June Investor Conferences GlobeNewswire
May-30-18 07:30AM  Mustang Bio Announces Preclinical Data on Potency of its CAR T Cells in Glioblastoma Published in JCI Insight GlobeNewswire
May-17-18 07:40AM  Mustang Bio, Inc. (MBIO) Enters Oversold Territory Zacks
May-14-18 05:30PM  Mustang Bio Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-27-18 08:43AM  Mustang Bio (MBIO) is Oversold: Can It Recover? Zacks
Apr-06-18 09:55AM  Mustang Bio (MBIO) Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-04-18 08:00AM  Mustang Bio to Present at Biotech Innovations Conference GlobeNewswire
Mar-29-18 04:30PM  Mustang Bio Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights GlobeNewswire
Mar-19-18 07:45AM  Mustang Bio to Present at CAR-T Congress USA GlobeNewswire -6.01%
Mar-15-18 07:30AM  Mustang Bio Announces Key Leadership Appointments GlobeNewswire
Mar-13-18 07:45AM  Mustang Bio to Present at March Investor Conferences GlobeNewswire
Mar-12-18 07:45AM  Mustang Bio to Present at the 255th American Chemical Society National Meeting & Exposition GlobeNewswire
Feb-06-18 08:30AM  Mustang Bio to Participate in Immuno-Oncology Panel at BIO CEO & Investor Conference GlobeNewswire
Dec-14-17 07:30AM  Mustang Bio to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 10, 2018 GlobeNewswire
Dec-11-17 04:30PM  Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial GlobeNewswire
04:30PM  Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Dec-04-17 08:30AM  Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies GlobeNewswire
Nov-14-17 08:30AM  Mustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights GlobeNewswire -6.04%
08:30AM  Mustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate Controller GlobeNewswire
Nov-01-17 09:05AM  Mustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting GlobeNewswire
Oct-31-17 07:30AM  Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain GlobeNewswire +17.62%
Oct-30-17 07:30AM  Mustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts GlobeNewswire +13.14%
Oct-11-17 07:30AM  Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma GlobeNewswire
Sep-14-17 08:00AM  Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies GlobeNewswire
Sep-05-17 07:30AM  Mustang Bio to Present at the CAR-TCR Summit 2017 GlobeNewswire
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma. It also develops MB-104, a CS1 CAR T, which is in Preclinical study for multiple myeloma and light chain amyloidosisy; MB-103, a human epidermal growth factor receptor 2 CAR T that is in Preclinical study to treat glioblastoma multiforme and metastatic breast cancer to brain; and MB-105, a prostate stem-cell antigen CAR T for prostate and pancreatic cancers. The company has a partnership agreement with the City of Hope National Medical Center and Fred Hutchinson Cancer Research Center to develop proprietary CAR T therapies across various cancers. It also holds a license agreement with Harvard University; and a research collaboration agreement with Beth Israel Deaconess Medical Center for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.